Shaji Kumar on Later Lines of Treatment for Myeloma

After cancer, I've been learning to maintain a positive attitude regarding my self-image and rehabilitation.

From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.

The Food and Drug Administration approved Abecma for adults with relapsed or refractory multiple myeloma who have received two or more previous lines of therapy.

In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.

Of everything I've ever done, I wonder how my multiple myeloma came to be.

An FDA committee voted that the benefits of Carvykti outweigh the risks for myeloma treatment, though concerns about secondary malignancies remain.